Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Reducing or holding anticoagulation and anti-platelet medications Anticoagulation and antiplatelet therapy, most often warfarin and aspirin, are standard of care in patients with CF-LVAD. Lowering or holding the dose of anticoagulation therapy and holding antiplatelet therapy for severe or recurrent bleeding are common first steps in the treatment of these patients. However, these approaches tip the balance towards the thrombotic side and might result in a devastating TE event.
By Abbas Bitar, MD, as told to Stephanie Watson Our understanding of heart failure has evolved tremendously over the last couple of decades. In the past, we treated heart failure with medicines only, and we were limited in what we could do for people with this condition. Now we can offer patients more advanced therapies that help them live longer with a better quality of life.
Pump thrombosis and hemolysis in patients with left ventricular assist devices (LVADs) are associated with significant morbidity and mortality. Intensification of anticoagulation has been suggested as potential therapy, with mixed results. The aim of this study is to assess the safety and efficacy of adding eptifibatide with or without an anticoagulation agent in managing patients with LVAD presenting with hemolysis and suspected pump thrombosis.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
